Literature DB >> 30098143

Genetic Penetrance of Macular Telangiectasia Type 2.

Cecinio C Ronquillo1, Kimberley Wegner1, Charles M Calvo1, Paul S Bernstein1.   

Abstract

Importance: The apparent genetic penetrance of macular telangiectasia type 2 (MacTel) is important for gene discovery studies and for clinical risk assessment of affected individuals' family members. Objective: To determine the genetic penetrance of MacTel. Design, Setting, and Participants: Descriptive cross-sectional study of patients with MacTel at a tertiary referral eye center. From 2008 to 2016, consecutive patients with MacTel were independently identified, and all of their available siblings and parents were recruited. Seventeen probands with MacTel were included in the study who satisfied the requirement of having at least 1 parent or sibling willing and able to participate. Data from these 17 families were included for the analysis of apparent genetic penetrance. Main Outcomes and Measures: Determination of MacTel genetic penetrance in probands' parents and siblings.
Results: Of 80 study participants, 50 (62.5%) were women. The mean (SD) age of study participants with MacTel was 61.2 (14.0) years (range, 23-81 years) and without MacTel was 60.7 (16.4) years (range, 24-92 years). There were 17 MacTel probands, and there was a high rate of enrollment of living siblings and parents: 52 of 71 living siblings (73%) and 11 of 12 parents (92%). Of 52 enrolled siblings, 9 (17%) were affected. Of 11 enrolled parents, 3 (27%) had MacTel. Apparent genetic penetrance was calculated to be 0.35 (95% CI, 0.14-0.6) by sibling analysis and 0.55 (95% CI, 0.02-1.00) by parent analysis. Combining the sibling and parent analyses, the apparent penetrance was calculated to be 0.38 (95% CI, 0.19-0.57). Conclusions and Relevance: The genetic penetrance of MacTel in rigorously phenotyped multiple large families is described. Families such as these could be critical for successful identification of MacTel genes.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30098143      PMCID: PMC6233841          DOI: 10.1001/jamaophthalmol.2018.3283

Source DB:  PubMed          Journal:  JAMA Ophthalmol        ISSN: 2168-6165            Impact factor:   7.389


  12 in total

1.  Bilateral juxtafoveal telangiectasis in a family.

Authors:  K T Oh; D W Park
Journal:  Retina       Date:  1999       Impact factor: 4.256

2.  Genome-wide analyses identify common variants associated with macular telangiectasia type 2.

Authors:  Thomas S Scerri; Anna Quaglieri; Carolyn Cai; Jana Zernant; Nori Matsunami; Lisa Baird; Lea Scheppke; Roberto Bonelli; Lawrence A Yannuzzi; Martin Friedlander; Catherine A Egan; Marcus Fruttiger; Mark Leppert; Rando Allikmets; Melanie Bahlo
Journal:  Nat Genet       Date:  2017-02-27       Impact factor: 38.330

3.  Idiopathic macular telangiectasia.

Authors:  Lawrence A Yannuzzi; Anne M C Bardal; K Bailey Freund; Kuan-Jen Chen; Chiara M Eandi; Barbara Blodi
Journal:  Arch Ophthalmol       Date:  2006-04

4.  Idiopathic juxtafoveolar retinal telangiectasis.

Authors:  J D Gass; R T Oyakawa
Journal:  Arch Ophthalmol       Date:  1982-05

Review 5.  MACULAR TELANGIECTASIA TYPE 2 IN AN OTHERWISE HEALTHY TEENAGE BOY WITH CONSANGUINEOUS PARENTS.

Authors:  Christina L Ryu; Mikel Mikhail; Ayesha Khan; John C Chen; Amer Omar
Journal:  Retin Cases Brief Rep       Date:  2018 Summer

6.  Focal parafoveal retinal telangiectasis.

Authors:  W L Hutton; W B Snyder; D Fuller; A Vaiser
Journal:  Arch Ophthalmol       Date:  1978-08

7.  Idiopathic juxtafoveolar retinal telangiectasis. Update of classification and follow-up study.

Authors:  J D Gass; B A Blodi
Journal:  Ophthalmology       Date:  1993-10       Impact factor: 12.079

8.  Fluorescence Lifetime Imaging Ophthalmoscopy: A Novel Way to Assess Macular Telangiectasia Type 2.

Authors:  Lydia Sauer; Rebekah H Gensure; Martin Hammer; Paul S Bernstein
Journal:  Ophthalmol Retina       Date:  2017-12-08

9.  World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.

Authors: 
Journal:  JAMA       Date:  2013-11-27       Impact factor: 56.272

10.  Identification of a potential susceptibility locus for macular telangiectasia type 2.

Authors:  Nancy L Parmalee; Carl Schubert; Maria Figueroa; Alan C Bird; Tunde Peto; Mark C Gillies; Paul S Bernstein; Krzysztof Kiryluk; Joseph D Terwilliger; Rando Allikmets
Journal:  PLoS One       Date:  2012-08-31       Impact factor: 3.752

View more
  4 in total

1.  Serine and Lipid Metabolism in Macular Disease and Peripheral Neuropathy.

Authors:  Marin L Gantner; Kevin Eade; Martina Wallace; Michal K Handzlik; Regis Fallon; Jennifer Trombley; Roberto Bonelli; Sarah Giles; Sarah Harkins-Perry; Tjebo F C Heeren; Lydia Sauer; Yoichiro Ideguchi; Michelle Baldini; Lea Scheppke; Michael I Dorrell; Maki Kitano; Barbara J Hart; Carolyn Cai; Takayuki Nagasaki; Mehmet G Badur; Mali Okada; Sasha M Woods; Catherine Egan; Mark Gillies; Robyn Guymer; Florian Eichler; Melanie Bahlo; Marcus Fruttiger; Rando Allikmets; Paul S Bernstein; Christian M Metallo; Martin Friedlander
Journal:  N Engl J Med       Date:  2019-09-11       Impact factor: 91.245

2.  FLUORESCENCE LIFETIME IMAGING OPHTHALMOSCOPY (FLIO) PATTERNS IN CLINICALLY UNAFFECTED CHILDREN OF MACULAR TELANGIECTASIA TYPE 2 (MACTEL) PATIENTS.

Authors:  Lydia Sauer; Alexandra S Vitale; Karl M Andersen; Barbara Hart; Paul S Bernstein
Journal:  Retina       Date:  2020-04       Impact factor: 3.975

3.  Multimodal imaging of macular telangiectasia type 2 in a pediatric patient.

Authors:  Magdy Moussa; Mahmoud Leila; Omar Moussa
Journal:  Am J Ophthalmol Case Rep       Date:  2021-04-01

4.  Systemic lipid dysregulation is a risk factor for macular neurodegenerative disease.

Authors:  Roberto Bonelli; Sasha M Woods; Brendan R E Ansell; Tjebo F C Heeren; Catherine A Egan; Kamron N Khan; Robyn Guymer; Jennifer Trombley; Martin Friedlander; Melanie Bahlo; Marcus Fruttiger
Journal:  Sci Rep       Date:  2020-07-22       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.